Diabetes Drugs: US FDA Advice On Premarketing Safety Database Raises Industry Concerns
Executive Summary
A draft guidance recommendation for 4,000 patient-years of exposure in Phase III, including at least 1,200 patients with comorbid conditions, is too proscriptive, unnecessarily large and lacks justification, biopharma industry comments say.